All In Biotech

Drug Trial Radar · NCT03734016

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 652 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

652

Actual

Start

Nov 1, 2018

Primary completion

Aug 8, 2022

Study completion Feb 28, 2024

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Nov 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • ZanubrutinibDrug

    160 mg orally twice daily

  • IbrutinibDrug

    Ibrutinib 420 mg orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) Assessed by the InvestigatorTime frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
  2. ORR Assessed by the Independent Review Committee (IRC)Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Locations

115 sites in 15 countries. Site status is shown where the registry gives one.

  • Carti Cancer Center

    Little Rock, Arkansas

  • David Geffen School of Medicine At UCLA

    Los Angeles, California

  • Rocky Mountain Cancer Centers Boulder

    Boulder, Colorado

  • Scri Florida Cancer Specialists South

    Fort Myers, Florida

  • Scri Florida Cancer Specialists North

    St. Petersburg, Florida

  • Augusta University

    Augusta, Georgia

  • Norton Cancer Institute Pavilion

    Louisville, Kentucky

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Forrest General Hospital Cancer Center

    Hattiesburg, Mississippi

  • Scri Hca Midwest Health

    Kansas City, Missouri

  • Nebraska Medical Center

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Atlantic Health System

    Morristown, New Jersey

  • Morristown Medical Center

    Morristown, New Jersey

  • Columbia University Medical Center

    New York, New York

  • Clinical Research Alliance, Inc

    Westbury, New York

  • Duke University Hospital

    Durham, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Willamette Valley Cancer Center

    Springfield, Oregon

  • Scri Tennessee Oncology Chattanooga

    Chattanooga, Tennessee

  • Sarah Cannon Cancer Center

    Nashville, Tennessee

  • Texas Oncology Fort Worth Cancer Center

    Fort Worth, Texas

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas

  • Joe Arrington Cancer Research and Treatment Center

    Lubbock, Texas

  • Texas Oncology San Antonio Medical Center Usor

    San Antonio, Texas

  • Texas Oncology Tyler Longview

    Tyler, Texas

  • Blue Ridge Cancer Care (Oncology and Hematology Associates of Southwest Virginia)

    Roanoke, Virginia

  • Va Puget Sound Health Care System

    Seattle, Washington

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Medical Oncology Associates

    Spokane, Washington

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Princess Alexandra Hospital

    Brisbane, Queensland, Australia

  • Icon Cancer Foundation

    South Brisbane, Queensland, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Peninsula Private Hospital

    Frankston, Victoria, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

  • Gasthuiszusters Antwerpen Sint Augustinus

    Wilrijk, Belgium

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.